HOW THE FDA IS BECOMING A DRUG COMPANY PART 2 of 2

Not a single Senator raised one concern about the significant safety issues inherent in the Critical Path Initiative/Reagan-Udall Foundation or conflicts of interest when Big Pharma and the FDA work side by side to develop, patent, and license drugs. The entire history of von Eschenbach’s relationship with Big Pharma, Big Biotech, and C-Change has been conveniently ignored. This issue now moves to the House, where it will be interesting to see if Representatives are as poorly informed as Senators as to what is actually going on.

Yes, the FDA is going into the drug development business. According to Senate bill S.1082, the purpose of the Foundation is to advance the mission of the Food and Drug Administration to modernize medical, veterinary, food, food ingredient, and cosmetic product development, accelerate innovation, and enhance product safety.

It will do this by taking into consideration the Critical Path reports and priorities published by the Food and Drug Administration, identify unmet needs in the development, manufacture, and evaluation of the safety and effectiveness, including postapproval, of devices, including diagnostics, biologics, and drugs, and the safety of food, food ingredients, and cosmetics.

The board of directors is composed of four primary members: the Commissioner of the FDA, the Director of the National Institutes of Health, the Director of the Centers for Disease Control and Prevention, the Director of the Agency for Healthcare Research and Quality. These members will then select the remaining board members to be composed of 4 representatives from Big Pharma and Big Biotech, 3 representatives from academia (which is funded by Big Pharma), 2 more from the FDA and NIH, 2 from consumers groups, and 1 from health care providers. This means that the FDA/Big Pharma/Big Biotech voting block always has 13 votes – to at the most 3. An executive director of the Foundation will be appointed by the board and serve at the pleasure of the board.

The bill says the Foundation will ensure that “action is taken as necessary to enable the licensing of inventions developed by the Foundation or with funds from the Foundation; and (C) executed licenses, memoranda of understanding, material transfer agreements, contracts, and other such instruments, promote, to the maximum extent practicable, the broadest conversion to commercial and noncommercial applications of licensed and patented inventions of the Foundation.”

Since the Foundation is responding to the needs of the Critical Path Initiative, and that initiative is primarily about the development of new drugs, it is clear that the Foundation will not only help with drug development but it will have significant business relationships as a result. Do not be confused by the Foundation’s non-profit status, this is simply a useful vehicle that SRI International has used to coordinate collaboration while securing patents and licenses and then spinning off business ventures. The FDA is trying to reduce its legal liability to the federal government by setting up the Regan-Udall Foundation as a non-profit, in case the drugs it helps design injure or kill people. Make no mistake about it, the FDA will be fully in control of the Reagan-Udall Foundation for the FDA. Once this becomes law, as anticipated by September 30, 2007, we will enter a new era with the FDA as a quasi drug company.

A Safety Nightmare

It is indeed disturbing that SRI International is intimately involved with the drug development process and has equally extensive connections with Homeland Security and the Defense Department. It will be far easier to make biological weapons that disrupt gene function than it will be to cure anything, in terms of initial applications of Critical Path technology. Indeed, this is an international problem and could cause an arms race of a new sort, as the Reagan-Udall licensed technology moves out into the world and not only creates a generic biotech drug industry but a generic biotech military industry. It would be responsible for the Congress to actually consider this problem before letting the Jeanie out of the bottle.

On the drug development side von Eschenbach plans to replace clinical trials that show positive outcomes such as true improvement in the medical condition or improved life expectancy with studies based on biomarkers or surrogate endpoints. Biomarkers are like sign posts that point the way, but do not guarantee that anything positive is actually happening. This concept lowers the safety and effectiveness testing required to get an approval, a key theme of the Critical Path Initiative.

This use of biomarkers, in and of itself, represents a drastic reduction in safety for Americans. One example of this problem is the Avandia scandal, wherein the drug was approved based on its ability to lower blood sugar (a surrogate endpoint or biomarker). It turns out that the drug does so while increasing the risk for heart failure, heart attack, and mortality. Over an eight year period it was turned into a blockbuster drug with sales of 3.2 billion a year. During this time the FDA sat on the known risks and did almost nothing to determine the aftermarket safety of the drug.

The problem was actually exposed by an independent researcher. Based on last year’s drug sales and the increased risk for heart attack, it is likely that 35,000 people needlessly died last year alone. How will independent researchers expose problems in the future when all of the advance technology required to evaluate the issue is part of an FDA-controlled monopoly?

Biotech drugs are inherently dangerous as they throw gene switches and powerfully influence functions of the body. Our understanding of what we are doing is in its infancy. This is like having the discovery of matches to light fires and not having any firefighting equipment or technology. Take the biotech company Amgen, with annual sales of 14.3 billion in 2006, and nearly half that revenue coming from two biotech drugs, Epogen and Aranesp, used in kidney disease. Aranesp is the blockbuster with 4.1 billion in sales for 2006, and is also used to treat anemia during chemotherapy. Amgen stock and sales are taking a beating as it is now coming to light that these drugs pose a significant risk for increased death when used, and doctors keep using them in an inappropriate way even though the FDA has warned them not to.

The FDA is scrambling to contain the damage the drug is causing without making Amgen look bad. Otherwise, the whole fast track approval of new biotech drugs as envisioned by the Critical Path Initiative and Reagan-Udall Foundation is in jeopardy. This is because these Amgen drugs were approved by the FDA based on biomarkers, not based on improved patient outcomes. An FDA Advisory panel was surprised to find how little testing Amgen did to demonstrate these drugs are safe or actually improve the patient’s health. Amgen has a long history of involvement with the American Cancer Society and its fundraising activities. Will an FDA chief that is beholden to the same circle of friends and a true believer in what Amgen stands for actually be able to objectively regulate the company and protect patients from danger? Or will the profits of the drug company and image of the Critical Path Initiative be more important?

The Loss of Patient Centered Care

There was a time when a patient walking into the doctor’s office actually had a meaningful conversation. The amount of time spent and the type of lab work or diagnostics performed were not constrained by managed care. To the best of the doctor’s ability, the patient was given personalized care in the best interest of the patient. Patient centered care has been replaced by time constraints, minimized diagnostics, and maximized dispensing of questionable drugs. All of these problems are about to get significantly worse, as we enter the new era of von Eschenbach’s concept of personalized medicine, based on genomics and proteomics.

Initially, a flood of new biotech drugs will hit the market, resulting in numerous Avandia and Vioxx-like scandals, which in some cases may take several years to identify. Congress, with 20-20 hindsight, will hold hearings that will result in legislation to improve safety. Von Eschenbach will tell Congress that the fault is not the drugs. Rather, it is the inability to personalize those drugs to specific patients that is the problem. Von Eschenbach would love to say that today, but he knows he doesn’t have the technology ready to implement this plan as he will in five years.

Thus, he is willing to put the lives of hundreds of thousands of innocent Americans in jeopardy by exposure to barely tested biotech drugs and recklessly push forward with his Critical Path Initiative plan.

The Von Eschenbach solution will be to evaluate the blood of every patient taking the drug with the FDA’s sophisticated biomarker software. The FDA has already developed the early stages of this software and will continue to perfect its new system of medicine over the next decade. Making a long story short, in order to receive medical care your blood will be evaluated by an FDA-controlled super computer, your genes will be profiled, your genetic weaknesses will be part of your medical record, and you will have an RFID chip in your arm storing your complex biological medical records, tracking your vital signs, and monitoring your whereabouts. If doctors think they have it bad now just wait until they become slaves to the FDA computer’s directions and drug prescriptions – which will no doubt be the latest and most expensive biotech drug experiment.

Loss of Health Options

The FDA knows that most of its Critical Path technology is years from practical application, thus it is confronted by the problem of maintaining funding while not much is happening. One aspect of this technology is very advanced toxicology tools, tools required for the development of new drugs. In January of this year the FDA issued a press release saying they want to use Critical Path science to develop tools to assist with their regular FDA duties:

Scientific advances hold the potential to improve the tools FDA uses to evaluate the safety and efficacy of human and veterinary products as well as the safety and nutrition of food and food ingredients (e.g., new rapid tests for biological and chemical contamination of animal-derived foods, technologies for detecting and mitigating the microbial contamination of food, analysis technologies for assessing the safety and nutritive value of foods and food ingredients).

While any person is in favor of the FDA being able to better identify contamination in food, such as infectious E.coli, assessing the safety of food and food ingredients is an entirely different matter. Similar language has been written into S.1082 in the section on the Reagan-Udall Foundation for the FDA, meaning the FDA is seeking to have it written into law that it can use Critical Path toxicology assessment to determine the safety of food ingredients (i.e., dietary supplements). This becomes a vehicle for the FDA to be able to remove any dietary supplement it desires from the market at its whim.

The supplements most likely to be removed are those that compete with Big Pharma and Big Biotech drugs, especially those drugs produced by the Reagan-Udall Foundation itself. S.1082 already contains the troublesome wording. The battle now moves to the House where it is vital to get an amendment into this legislation that will protect dietary supplements without interfering with the FDA’s ability to identify true food contamination problems. This amendment has been prepared by Jonathan Emord, our nation’s top health freedom attorney.

To keep up to date on this legislation and to help preserve your access to dietary supplements, send an email your Senators and Representative by clicking here.

A great deal will be happening in the next month or two on this legislation, which will determine the future of health care safety and quality for many years to come. Ideally, the Reagan-Udall Foundation for the FDA should be removed from this legislation altogether until the technology is ready and the safety can be assured. Realistically, both the Senate and House are going to pass this legislation with the Reagan-Udall Foundation in the bill – unless massive public protest occurs.

Assuming that the Reagan-Udall Foundation does move forward, strong language will need to be in this legislation to preserve health freedom and protect consumers from having dietary supplements evaluated using drug-related risk benefit analysis. In addition to the Emord amendment it will be essential to protect ourselves from the FDA’s internal conflicts of interest that pervade the agency. As things are now the FDA is more concerned about looking good and protecting its image than it is about drug safety or allowing unfettered access to safe and effective forms of natural health options. Alternative therapies and dietary supplements are the true competition to the FDA’s Big Pharma and Big Biotech medical model it is seeking to cram down the throats of all Americans. Stay tuned – more to come. For part 1 click below.

Click here for part -----> 1,

Byron J. Richards, Founder/Director of Wellness Resources, is a Board-Certified Clinical Nutritionist and nationally-renowned health expert, radio personality, and educator. He is the author of Mastering Leptin, The Leptin Diet, and Fight for Your Health: Exposing the FDA's Betrayal of America.

Richards encourages individuals to take charge of their health, stand up for their health rights, and not blindly succumb to propaganda from the vested-interests who profit from keeping Americans sick. As founder of Wellness Resources, Inc. of Minneapolis, MN, an independently-owned fine-quality dietary supplement company since 1985, he has personally developed 75 unique nutraceutical-grade nutritional formulas. www.wellnessresources.com

FREE Subscription to Byron's Health Newsletter, click here.

E-mail: byron@truthinwellness.com